News Summary

OncoHelix, a Canadian precision diagnostics company, has partnered with Desjardins Insurance to enhance access to advanced cancer genomic profiling for Canadians. This collaboration, part of Desjardins’ Cancer Care Focus Initiative, aims to reduce barriers to genomic testing, which is critical for precision oncology. By providing coverage for OncoHelix’s comprehensive cancer genomic profiling tests, Desjardins will enable more patients to benefit from precision diagnostics, allowing clinicians to make personalized treatment decisions. This initiative is a significant step towards democratizing access to precision oncology and improving outcomes for Canadians battling cancer.